🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer

Recruitingn/aAges any - anyMaleSanta Chiara Hospital
NCT06783127 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This is an observational, retrospective/prospective, multicenter study designed to define, overall survival, clinical outcomes and predictive/prognostic factors of a consecutive population of mCRPC patients treated with olaparib in clinical practice.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: BRCA mutant Metastatic castration-resistant prostate cancer patients treatment with olaparib in clinical practice Exclusion Criteria: Olaparib treatment in a clinical trial
💊

What it tests

  • Olaparib
📍

Where

2 sites
Sabrina Rossetti
Naples, Italy
Orazio Caffo
Trento, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy